The Insulin Pen Preferred by Patients

NovoLog^® Mix 70/30 FlexPen^® is preferred by patients^14,17

NovoLog^® Mix 70/30 FlexPen^® is easy to learn, easy to use, easy to read, and accurate. It's easy to see why it's the insulin pen preferred by patients.^14,17

Multicenter, randomized, open-label, crossover study of 121 patients with type 1 or 2 diabetes mellitus transferred from previous QD or BID conventional insulin therapy to NovoLog^® Mix 70/30, assessing patient preference, efficacy, and safety. Intent-to-treat population: N=105.¹⁷

^*6% of respondents had no preference

Multicenter, randomized, open-label, 2-way, crossover (two 12-week periods) trial in 137 insulin-experienced patients with type 2 diabetes mellitus comparing efficacy of, safety of, and device preference for NovoLog^® Mix 70/30 FlexPen^® and lispro mix 75/25 pen. Satisfaction with pen devices was assessed using 2 device-specific questionnaires and a comparative questionnaire at end of study. Intent-to-treat population: N=132.¹⁴

^†17% of respondents had no preference

NovoLog^® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) Indications and Usage

NovoLog^® Mix 70/30 is indicated for the treatment of patients with diabetes mellitus for the control of hyperglycemia.

NovoLog^® Mix 70/30 Important Safety Information

NovoLog^® Mix 70/30 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog^® Mix 70/30 or one of its excipients.

Because NovoLog^® Mix 70/30 has peak pharmacodynamic activity 1 hour after injection, it should be administered with meals. Hypoglycemia is the most common adverse effect of insulin therapy, including NovoLog^® Mix 70/30. As with all insulins, the timing of hypoglycemia may differ among various insulin formulations. Glucose monitoring is recommended for all patients with diabetes. Any change of insulin should be made cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, species, or method of manufacture may result in the need for a change in dosage. Potential side effects associated with the use of all insulins include hypoglycemia, hypokalemia, lipodystrophy, and allergic reactions.

Because of differences in the action of NovoLog^® Mix 70/30 and other insulins, care should be taken in patients in whom these conditions may be clinically relevant (eg, patients who are fasting, have autonomic neuropathy, are using potassium-lowering drugs, or are taking drugs sensitive to serum potassium level). Do not mix NovoLog^® Mix 70/30 with any other insulin product.

As with other insulin therapy, erythema, swelling, and pruritus at the injection site have been observed with NovoLog^® Mix 70/30. Less common but more serious are severe cases of generalized allergy, including anaphylactic reaction, which may be life threatening. NovoLog^® Mix 70/30 dose requirements may be reduced in the presence of renal impairment or impaired hepatic function. Changes in cross-reactive antibodies were more common after NovoLog^® Mix 70/30 than with human premixed 70/30, but the clinical significance of these antibodies has not been established. Frequency of adverse events comparable with that of human 70/30. Local injection site reactions comparable with those of human 70/30.

Please see Prescribing Information.

Levemir^®, NovoLog^®, NovoLog^® Mix 70/30, GlucaGen^®, HypoKit^®, and FlexPen^® are registered trademarks of Novo Nordisk A/S. NovoSeven^® RT and Norditropin^® are registered trademarks of Novo Nordisk Health Care AG. Activella^® 1.0 mg/0.5 mg, Activella^® 0.5 mg/0.1 mg, and Vagifem^® are registered trademarks of Novo Nordisk FemCare AG.